Resolving the Smoking Paradox: No Evidence for Smoking-Induced Preconditioning in Large Vessel Occlusion Stroke.


Journal

European neurology
ISSN: 1421-9913
Titre abrégé: Eur Neurol
Pays: Switzerland
ID NLM: 0150760

Informations de publication

Date de publication:
2023
Historique:
received: 16 03 2023
accepted: 21 07 2023
medline: 3 11 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Smoking is an established risk factor for stroke. However, several studies have reported a better outcome after stroke for patients who smoke. According to this "smoking paradox" hypothesis, smoking might promote less severe strokes, higher collateral scores, and smaller infarct cores. In this retrospective study, we screened data of 2,980 acute ischemic stroke patients with MCA-M1 occlusion treated with mechanical thrombectomy. Patients were categorized according to smoking status (current, former, or never). We assessed univariate associations between clinical characteristics and smoking status. Subsequently, we used adjusted regression analysis to evaluate associations of smoking with stroke severity on admission (National Institutes of Health Stroke Scale [NIHSS]; primary endpoint), infarct core volume, and collateral status (secondary endpoints). Out of 320 patients, 19.7% (n = 63) were current smokers and 18.8% (n = 60) were former smokers. Admission NIHSS, reperfusion success, and modified Rankin Scale (mRS) after 3-6 months were similar in all groups. Current smokers were younger, more often male and less likely to have atrial fibrillation compared to former and never smokers. In regression analyses, smoking status was neither associated with admission NIHSS (estimate 0.54, 95% confidence interval [CI]: -1.27-2.35, p = 0.557) nor with collateral status (estimate 0.79, 95% CI: 0.44-1.44, p = 0.447) or infarct core volume (estimate -0.69, 95% CI: -15.15-13.77, p = 0.925 for current vs. never smokers). We could not confirm the smoking paradox. Our results support the fact that smoking causes stroke at a younger age, highlighting the role of smoking as a modifiable vascular risk factor.

Identifiants

pubmed: 37562368
pii: 000533436
doi: 10.1159/000533436
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-333

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Roni E Widmer (RE)

Department of Neurology, University Hospital Zurich, Zurich, Switzerland, RoniEsther.Widmer@usz.ch.
Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland, RoniEsther.Widmer@usz.ch.

Andrea Bink (A)

Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland.

Janne Hamann (J)

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Lisa Herzog (L)

Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.
Institute of Data Analysis and Process Design, ZHAW Winterthur, Winterthur, Switzerland.

Mohamad El Amki (M)

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Hakan Sarikaya (H)

Department of Neurology, InselSpital Bern, Bern, Switzerland.

Zsolt Kulcsar (Z)

Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland.

Andreas R Luft (AR)

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Cereneo Center for Neurology and Rehabilitation, Vitznau, Switzerland.

Susanne Wegener (S)

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH